长效醋酸甲羟孕酮与脑膜瘤的流行病学与临床关联
本文汇总流行病学与临床数据,指出脑膜瘤在女性中更常见且多数表达孕激素受体(PR),多种孕激素(如醋酸环丙孕酮)与脑膜瘤相关。近期国际流行病学研究显示,广泛使用的注射避孕药长效醋酸甲羟孕酮(DMPA,商品名 Depo-Provera)使脑膜瘤风险升高 1.5–5.5 倍,且开颅切除风险亦升高,故有脑膜瘤病史者应避免使用。
要点
- DMPA 暴露使脑膜瘤风险升高 1.5–5.5 倍,绝对风险仍小。
- DMPA 暴露后不仅诊断风险升高,开颅切除风险亦升高。
- 有脑膜瘤病史者在有替代方案时应避免使用 DMPA。
核心结论
- 流行病学与临床数据将长效醋酸甲羟孕酮(DMPA)与脑膜瘤联系起来。
- 暴露于 DMPA 使脑膜瘤风险升高 1.5–5.5 倍,绝对风险仍小。
- DMPA 暴露后开颅切除肿瘤的风险亦升高,具有临床意义。
- 有脑膜瘤病史者在有替代方案时应避免使用 DMPA。
研究设计与样本
- 综述性汇总:整合既往及近期国际流行病学与临床数据。
- 研究对象为脑膜瘤与孕激素暴露(含 DMPA)的关联。
- 文中未报告具体研究设计细节与样本量。
主要发现
- 多数脑膜瘤表达孕激素受体(PR),孕激素暴露差异可能促成性别差异。
- 多种孕激素(如醋酸环丙孕酮 CPA)已被证实与脑膜瘤相关。
- 近期国际流行病学研究发现 DMPA 与脑膜瘤风险显著升高相关。
- DMPA 暴露使脑膜瘤风险升高 1.5–5.5 倍。
- DMPA 暴露后开颅切除风险升高,不仅限于肿瘤诊断风险。
关键数值与推荐
- DMPA 暴露相关脑膜瘤风险升高幅度为 1.5–5.5 倍。
- 有脑膜瘤病史者,在有替代方案时应避免使用 DMPA。
- DMPA 咨询时应与患者讨论脑膜瘤风险。
- 长期 DMPA 暴露者是否应筛查脑膜瘤尚待研究。
临床怎么用
- 向使用 DMPA 的患者告知脑膜瘤风险。
- 有脑膜瘤病史者优先选择替代避孕方案。
- 对长期 DMPA 暴露者的脑膜瘤筛查价值需进一步研究。
局限性
- DMPA 相关脑膜瘤的绝对风险仍较小。
- PR 信号在脑膜瘤中的机制尚待阐明。
- 肿瘤基因组、激素暴露与信号及社会结构因素对健康差异的复杂交互尚需研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Meningiomas are among the few intracranial tumors that are more common in females than males. The majority of meningiomas express progesterone receptor (PR), and differences in exposure to progestogens are thought to contribute to sex-based disparity in meningioma. Previous epidemiological and clinical data have demonstrated that multiple progestins, such as cyproterone acetate (CPA), are linked to meningioma. More recently, international epidemiological studies have found a significantly increased risk of meningioma with depot medroxyprogesterone acetate (DMPA), a widely used injectable contraceptive sold under the trade name Depo-Provera. Although the absolute risk of meningioma remains small, exposure to DMPA increases the risk of meningioma by 1.5- to 5.5-fold. DMPA-associated meningiomas are clinically significant, as the risk of craniotomy for tumor resection, not just the risk of tumor diagnosis, is elevated after DMPA exposure. These data suggest that DMPA should be avoided in individuals with a history of meningioma when alternatives are available. The risk of meningioma should be discussed with patients during DMPA counseling, and the utility of screening patients with prolonged DMPA exposure for meningiomas should be investigated. Further work is needed to elucidate the mechanisms of PR signaling in meningioma and to understand the complex interplay of tumor genomics, hormone exposure and signaling, and social and structural drivers of health that may contribute to disparities in meningioma.
引用
- Braman BC, Cady MA, Merz-Herrala AA, et al. Epidemiological and clinical data link depot medroxyprogesterone acetate to meningioma. Neuro Oncol. 2026. PMID: 42166750. doi:10.1093/neuonc/noag115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。